Brieflands
History
The company was first founded by Seyyed M. Miri and Seyed-M Alavian as an editorial group in a Medical Institute in 2007 to publish its medical journal. After three years of experience, the number of journals increased to 5 journals, and the company launched its first form of business as a VOF (collaboration) professional STM company in Heerlen, the Netherlands, which was called "Kowsarmedical Publishing." Respecting the publishing services (from submission to publishing), especially an in-house "Journal Management System," our journals increased to more than 60 STM journals between 2010 and 2019. Since 2022, "Brieflands" is the new brand name that acts as a "Science, Technical, Medical Publisher" that publishes more than 50 journals with the services provided by 97 expert employees in three different branches.
Business Profile
- Brieflands is a Registered Trademark with record number 1454012.
- Brieflands has been registered as a General partnership (Vennootschap onder firma) company in the Chamber of Commerce (Kamer van Koophandel) of the Netherlands since 2010.
- KvK number: 89235444.
- BTW (VAT) number: NL864918896B01 (check online at VIES)
- RSIN: 864918896
- Nedmedica is our related company which is specialized in Author Services.
- Our former branding name was Kowsarmedical Publishing (2010-2021).
Communities in Brieflands
Select a community to browse its collections.
Recent Submissions
Histopathological and Immunohistochemical Changes in Coronary Arteries Following Percutaneous Coronary Intervention in Patients Undergoing Coronary Artery Bypass Grafting
(Brieflands, 2026-06-30) Mahmood Beheshti Monfared; Atoosa Gharib; Sahand Abrishami; Mahmood Beheshti Monfared [0000-0002-1874-4273]
Background: Coronary artery disease (CAD) is a leading indication for coronary artery bypass grafting (CABG). Many patients undergo percutaneous coronary intervention (PCI) with stent implantation before subsequently requiring CABG. Objectives: This study aimed to evaluate and compare histopathological and immunohistochemical changes in the coronary artery walls of CABG candidates with and without a history of PCI. Methods: In this case-control study, patients with CAD undergoing CABG were allocated to two groups based on their history of PCI. During surgery, coronary artery tissue specimens were obtained from the arteriotomy edge at the distal anastomotic site. Histopathological evaluation included assessment of atherosclerotic plaques, endothelial injury, extracellular matrix degradation, and immunohistochemical expression of CD68, CD45RO, and α-smooth muscle actin (α-SMA). The frequencies of these pathological features were compared between the two groups. Results: Patients with a history of PCI exhibited significantly higher expression of the inflammatory markers CD68 and CD45RO and the proliferative marker α-SMA than the control group (P < 0.05). In contrast, no significant differences were observed between the groups in extracellular matrix degradation, collagen content, or the severity of endothelial injury. Furthermore, the timing of intervention (urgent vs emergent) was not associated with the extent of histopathological changes. Conclusions: PCI before CABG was associated with an active inflammatory state and an enhanced proliferative response in the coronary artery wall. These changes occurred in the absence of substantial structural disruption of the extracellular matrix, suggesting that coronary stenting induces persistent immune activation and vascular smooth muscle cell proliferation rather than overt tissue destruction.
Targeted Biologic and Cellular Therapies for Systemic Lupus Erythematosus: Current Evidence and Future Perspectives
(Brieflands, 2026-06-30) Reyhaneh Taheri; Cobra Moradian; Cobra Moradian [0000-0002-3948-4642]
Context: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by heterogeneous clinical manifestations and dysregulated innate and adaptive immune responses. Conventional management relies largely on immunosuppressants, which pose challenges for long-term efficacy and sustained disease control. Recent therapeutic advances have introduced monoclonal antibodies as a more targeted approach to disease control. Evidence Acquisition: A comprehensive literature search was conducted in PubMed, Scopus, Web of Science, and Embase from database inception to early 2026. The review included randomized controlled trials, pivotal phase II/III trials, long-term extension trials, observational cohort studies, systematic reviews and meta-analyses, and regulatory documents from the FDA and the EMA. Results: Anifrolumab, a monoclonal antibody that inhibits the type I interferon pathway, appears to improve SLE manifestations and to enable sustained reductions in the corticosteroid dose. B-cell-targeted therapies, including belimumab, rituximab, and obinutuzumab, together with novel agents targeting other immune pathways, offer promising therapeutic alternatives. Although several novel therapies have demonstrated clinical benefit in SLE, other experimental approaches, such as ustekinumab, have failed to show significant efficacy. Cell-based therapies, including anti-CD19 chimeric antigen receptor T-cell therapy, are emerging as investigational options for refractory disease. Conclusions: Emerging targeted and cell-based therapies represent a promising direction in SLE management by enabling more precise strategies for treatment-resistant disease; however, careful evaluation of their long-term safety, effectiveness, and accessibility is required.
The Imperative of Academic Resilience in Nursing Students During Wartime: A Neglected Priority
(Brieflands, 2026-09-30) Fereshteh Araghian Mojarad; Tahereh Yaghoubi; Fereshteh Araghian Mojarad [0000-0002-0147-3999]; Tahereh Yaghoubi [0000-0001-8526-6745]
This article does not have an abstract.
Information Gaps in the Care Pathway of Neurosurgical Patients: A Prerequisite Study for Electronic Health Record Design
(Brieflands, 2026-06-30) Mina Lazem; Sajjad Aliazdeh; Mina Lazem [0000-0002-2891-4571]; Sajjad Aliazdeh [0000-0002-2337-0309]
Background: Continuity of neurosurgical care depends on comprehensive documentation. This study identifies information gaps to guide electronic health record (EHR) design. Objectives: To assess the completeness of documentation across the entire neurosurgical care pathway, from admission to discharge, and identify gaps to inform EHR design. Methods: A retrospective review of 621 neurosurgical records was conducted using a 31-item checklist designed to assess documentation completeness across the entire care pathway. Results: Among the 621 records, the mean age was 51.8 ± 19.3 years, and 54.3% of patients were male. Demographic data were highly complete, with age documented in 98.2% and gender in 99.8% of records. However, substantial documentation deficits were identified: intraoperative complications were documented in only 15.8% of records, pupil examinations on intensive care unit (ICU) admission in 34.8%, active medication lists during ICU-to-ward transfer in 19.8%, and final pathology reports at discharge in only 23.8%. Conclusions: Significant but modifiable information gaps exist in current documentation systems, particularly during care transitions. These findings provide an evidence-based roadmap for phased, problem-oriented EHR implementation. Although the specific frequencies of these gaps may vary across settings, the pattern of transition-related gaps is likely applicable to other resource-limited neurosurgical centers.
Predictors of QTc Prolongation in Methadone Maintenance Treatment: A Cross-sectional Study from a Psychiatric Hospital Addiction Clinic
(Brieflands, 2026-09-30) Sina Pourmirza Langeroudi; Mohammadrasoul Khalkhali; Maryam Shakiba; Aboozar Fakhrmousavi; Mohammad Hassan Novin; Sina Pourmirza Langeroudi [0009-0009-5281-1300]; Mohammadrasoul Khalkhali [0000-0002-8824-4629]; Maryam Shakiba [0000-0002-7497-6001]; Aboozar Fakhrmousavi [0000-0001-5551-5499]; Mohammad Hassan Novin [0000-0002-7614-8146]
Background: Methadone maintenance treatment (MMT) is effective for opioid use disorder; however, methadone-associated QTc prolongation raises concerns about life-threatening arrhythmias. Real-world data on QTc prolongation and its determinants remain limited, particularly among patients with psychiatric comorbidities receiving multiple QT-prolonging medications. Objectives: This study aimed to determine the prevalence and independent predictors of QTc prolongation in a psychiatric hospital-based addiction clinic. Methods: This cross-sectional study (December 2024 - May 2025) enrolled adult patients receiving stable MMT (≥4 months) at Shafa Psychiatric Hospital, Iran. QTc prolongation was defined as > 450 ms (CTCAE Grade 1). Medications were classified according to CredibleMeds risk category. Multivariable binary logistic regression was used to identify independent predictors. Results: Among 120 participants (97.5% male; mean age, 49.6 ± 12.0 years), the prevalence of QTc prolongation was 12.5% (n = 15). In the primary model, a history of cardiac disease (OR = 26.59; 95% CI, 3.57 - 198.12; P = 0.001) and the use of moderate-risk QT medications (OR = 18.81; 95% CI, 2.76 - 128.06; P = 0.003) were significant predictors. A parsimonious sensitivity model confirmed these associations with more stable estimates (cardiac disease: OR = 10.60, P = 0.004; moderate-risk medications: OR = 8.23, P = 0.004). Methadone dose and duration were not significant predictors. Conclusions: Based on the sensitivity model, a history of cardiac disease and moderate-risk QT medications may be independently associated with QTc prolongation in MMT patients. Given the cross-sectional design and the limited number of events, these findings are exploratory. Consistency across models supports their potential clinical relevance and underscores the need for cardiac evaluation, ECG monitoring, and medication review.